Maxim Group Keeps Their Buy Rating on Actinium Pharmaceuticals (ATNM)

By Carrie Williams

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (ATNMResearch Report). The company’s shares closed last Friday at $9.28.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 28.5% and a 49.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Actinium Pharmaceuticals with a $65.00 average price target, a 587.8% upside from current levels. In a report issued on August 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $65.00 price target.

See today’s analyst top recommended stocks >>

Based on Actinium Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5.67 million. In comparison, last year the company had a GAAP net loss of $5.03 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.